Allogene Therapeutics, Inc.

Name: Allogene Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

ALLONasdaqCIK 1737287HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$4.6m, Q2 FY2026

Operating income−$46.9m, Q2 FY2026

Net income−$42.7m, Q2 FY2026

Allogene Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	4.6
Research and development	$m	46.0	54.7	52.3	50.4	44.7	45.0	50.2	40.2	31.2	28.6	32.0	30.7
Operating income	$m	(63.0)	(85.1)	(69.5)	(71.4)	(71.8)	(60.5)	(65.2)	(56.8)	(44.9)	(42.4)	(46.1)	(46.9)
Interest expense	$m	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.3	0.3	0.3	0.3
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	(62.3)	(85.8)	(65.0)	(66.4)	(66.3)	(59.9)	(59.7)	(50.9)	(41.4)	(38.8)	(42.6)	(42.7)
Diluted EPS	$ per share	(0.37)	not reported	(0.38)	(0.35)	(0.32)	not reported	(0.28)	(0.23)	(0.19)	not reported	(0.18)	(0.13)
Basic EPS	$ per share	(0.37)	not reported	(0.38)	(0.35)	(0.32)	not reported	(0.28)	(0.23)	(0.19)	not reported	(0.18)	(0.13)

Balance sheet

Cash and equivalents$38.6m, Q2 FY2026

Shareholders' equity$436.2m, Q2 FY2026

Allogene Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	69.2	83.2	51.0	171	51.2	75.2	42.5	52.3	37.8	51.7	30.3	38.6
Current assets	$m	473	459	395	457	304	303	292	283	261	258	273	340
Total assets	$m	713	643	586	647	589	549	508	471	440	416	396	550
Current liabilities	$m	37.5	37.1	30.9	37.3	32.6	35.5	30.0	31.7	31.8	32.5	28.3	31.7
Total liabilities	$m	133	131	125	132	125	127	123	126	124	123	117	114
Shareholders' equity	$m	581	512	461	515	464	422	385	345	315	293	279	436

Cash flow

Operating cash flow−$32.0m, Q2 FY2026

Capital expenditure$150.0k, Q2 FY2026

Allogene Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(55.5)	(53.7)	(55.9)	(63.6)	(44.1)	(36.7)	(52.9)	(39.0)	(29.7)	(27.6)	(12.9)	(32.0)
Capital expenditure	$m	0.0	0.2	0.0	0.0	0.4	0.3	0.1	0.0	0.2	0.0	0.0	0.2

Diluted shares (weighted)328.93m, Q2 FY2026

Allogene Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	144	145	147	168	169	190	209	215	219	222	240	329

Shares outstanding: 345.49m at Aug 10, 2026, from the cover of the 10-Q filed Aug 12, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.